The FDA is weighing the fate of Spark Therapeutics' voretigene neparvovec, potentially the first among a wave of new gene therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Morrison, C. Landmark gene therapy poised for US approval. Nat Rev Drug Discov 16, 739–741 (2017). https://doi.org/10.1038/nrd.2017.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.212